Weight Loss Medication: Fact or Fiction?

Fact:
Yes, prices have increased in some places due to high demand and supply shortages, but not to the extreme many posts suggest. Many pharmacies offer deals or subscription plans. You can also discuss switching to Wegovy, which may be more affordable depending on your country. Check our Trusted Suppliers list for regulated options..

Fiction:
Weight loss medication should be used in conjunction with amending your eating habits, improving your movement levels and adjusting your relationship with food. When you master this, you will be able to successfully maintain your weight loss when you stop taking the medication..

Fact:
Hair loss is not a direct effect of the drug. It usually happens because of telogen effluvium — when your body is under stress from rapid weight loss, calorie restriction, or nutrient shifts. Hair shedding is often temporary and improves as your body adapts. Adequate protein, vitamins, and overall nutrition can help reduce the impact.

Fact:

For some people. Fatigue is reported, usually from eating less, dehydration, or nutrient gaps. It’s often temporary, but persistent tiredness should be discussed with your prescribing doctor.

Fiction:

Extracting liquid from GLP-1 pens is unsafe. You won’t know the true dose, the drug can become contaminated, and dosing this way is not supported. The only safe dose is the one prescribed.

Fact:

For some people. Fatigue is reported, usually from eating less, dehydration, or nutrient gaps. It’s often temporary, but persistent tiredness should be discussed with your prescribing doctor.

Fact:

Sulphur-smelling burps are a commonly reported side effect of GLP-1 and dual-agonist weight-loss medications such as Mounjaro (tirzepatide) and Wegovy (semaglutide). These drugs slow stomach emptying, meaning food stays in the stomach longer and can ferment, producing sulphur-containing gas. Eating smaller meals, reducing fatty foods, and avoiding fizzy drinks can help reduce this side effect.

Fact: But it’s usually the weight loss, not the drug itself. Rapid weight loss increases gallstone risk, whether from diet, surgery, or medication. Staying hydrated and avoiding extreme calorie cuts may help

Fact: Sometimes. Women do report cycle changes. These are linked to weight loss and hormonal shifts, not the drug directly. If irregular bleeding continues, see a clinician.

Fiction:

Constipation is common but not universal. It happens because digestion slows and food volume drops. For many, more water, fibre, and light exercise solve it.

Fiction:

Some suppliers will enable you to switch to them if you have proof of your starting weight and copies of your prescriptions from your previous supplier. This is another reason why keeping track of you progress is important. Firstly it keeps you motivated and secondly it is important if you need to speak to another medical professional for any reason.

Fiction: These medications were originally developed for diabetes, but versions such as Wegovy (semaglutide) and Zepbound/Mounjaro (tirzepatide) are now approved specifically for medical weight loss. They are prescribed for people with obesity or overweight with health risks—not only for those with diabetes.

Fiction: Most people experience some weight regain after stopping GLP-1 medications because appetite hormones return to normal. Long-term success requires ongoing lifestyle changes, nutrition support, and physical activity, even after discontinuing medication.

Fact: GLP-1 and dual-agonist medications slow gastric emptying, which can cause nausea, fullness, reflux, and occasional vomiting—especially during dose increases. Eating smaller meals, reducing fatty or greasy foods, and increasing water intake can significantly reduce this side effect.

Fact: Some people experience increased alcohol sensitivity or feel intoxicated more quickly while on GLP-1 medications because the drugs slow digestion and may affect how alcohol is absorbed. Drinking slowly, eating beforehand, and limiting intake can help you avoid unwanted effects.

Fiction: Weight-loss medications like Mounjaro, Wegovy and Ozempic do not “stop working,” but weight loss naturally slows over time as the body adapts and calorie needs decrease. Plateaus are common with any weight-loss method. Adjusting nutrition, increasing protein intake, staying active, and following a structured medical weight-management plan can help restart progress

Fact: Multiple large analyses and clinical studies show that when people stop taking GLP-1 and dual-agonist weight-loss medications such as Wegovy (semaglutide) and Mounjaro (tirzepatide), much of the lost weight often returns over time. A major review published in The BMJ found people regained weight at roughly 0.4 kg (nearly 1 lb) per month after stopping treatment, with many returning to their pre-treatment weight within around 1.5–1.7 years. (Reuters)

Systematic analyses also show that people typically regain more than half of the weight lost within about a year of discontinuing GLP-1 therapy, indicating that sustained lifestyle support and long-term management are key to lasting results.

(en.wikipedia.org)

Fact: There are now two newly authorised oral GLP-1 medicines for weight management in the UK: oral semaglutide (Wegovy) and orforglipron (Foundayo). Both are prescription-only medicines and are authorised for eligible adults alongside a reduced-calorie diet and increased physical activity.

Fact: The MHRA authorised a tablet version of semaglutide (Wegovy) for weight management in the UK in June 2026. It is taken once daily and is authorised for eligible adults with obesity, or certain people who are overweight with a weight-related health condition.

Fact: Foundayo is the brand name for orforglipron, a new once-daily oral GLP-1 medicine from Eli Lilly. The MHRA authorised it in the UK on 10 August 2026 for weight management and type 2 diabetes. The UK was the first country in Europe to authorise it

Fiction: Foundayo and Mounjaro are different medicines.

Foundayo contains orforglipron, which is a GLP-1 receptor agonist. Mounjaro contains tirzepatide, which acts on both GLP-1 and GIP receptors.

Fact:
GLP-1 and dual-agonist medications slow gastric emptying, which can cause nausea, fullness, reflux, and occasional vomiting—especially during dose increases. Eating smaller meals, reducing fatty or greasy foods, and increasing water intake can significantly reduce this side effect.

Fact:
Both contain semaglutide, and recent research comparing results indirectly found that oral semaglutide 25 mg and injectable semaglutide 2.4 mg produced broadly comparable weight-loss outcomes. However, there has not been a direct head-to-head trial comparing the two formulations, so they should not simply be described as identical in effectiveness.

Research:
2026 indirect comparison of oral and injectable semaglutide

OASIS 4 oral semaglutide trial — New England Journal of Medicine

Fact:
The new Wegovy tablet should be taken once a day after at least eight hours of fasting, with no more than 120 mL of water. You should then wait at least 30 minutes before eating, drinking or taking other oral medicines.

Fiction:

The Wegovy tablet should not be taken at the same time as food, drinks or other oral medicines. The UK product information says to wait at least 30 minutes after taking the tablet before taking other oral medicines.

Fact:

Foundayo (orforglipron) can be taken once daily with or without food, at any time of day. This is different from the new Wegovy tablet, which has specific fasting and timing requirements.

Source:
Foundayo — UK Summary of Product Characteristics

Fact:

Foundayo contains orforglipron, an oral GLP-1 receptor agonist. It activates GLP-1 receptors involved in appetite regulation and reduces food intake; clinical trials have shown significant weight loss compared with placebo.

Research:
ATTAIN-1 trial — New England Journal of Medicine

UK product information:
Foundayo — UK Summary of Product Characteristics